8-K: Tevogen Bio Secures $6 Million Investment Through Series C Preferred Stock Offering

Tevogen Bio Holdings Inc. has entered into a securities purchase agreement, raising $6 million through the sale of Series C Preferred Stock to an existing investor.

Summary

• Tevogen Bio Holdings Inc. has secured a $6 million investment by selling 600 shares of Series C Preferred Stock to an existing investor.
• The Series C Preferred Stock is convertible into common stock six months after issuance, with the conversion price based on the volume-weighted average price of the common stock over the 30 trading days prior to conversion, subject to a floor price of $0.6172.
• To prevent the investor from exceeding a 9.99% ownership stake, the company will issue pre-funded warrants instead of common stock if necessary, unless the investor waives this limitation, up to a maximum of 19.99%.
• The Series C Preferred Stock carries a 7.5% annual cumulative dividend, compounded annually, payable in shares of Series C Preferred Stock or cash at the company's discretion, starting no later than September 30, 2024, and ending on September 30, 2034.
• The company has the right to call the Series C Preferred Stock at $10,000 per share after the fifth anniversary of the issuance date.
• A director, Suren Ajjarapu, resigned from the board effective August 21, 2024, with no reported disagreements with the company.
• The company filed a Certificate of Designation for the Series C Preferred Stock on August 22, 2024, outlining the rights and preferences of the new stock.

Sentiment

Score: 7

Explanation: The document indicates a positive development for the company, securing a significant investment. However, the terms of the preferred stock, such as the non-voting rights and call option, introduce some limitations for the investor, resulting in a moderately positive sentiment.

Positives

• The company successfully raised $6 million in funding.
• The investment provides capital for the company's operations.
• The conversion feature of the preferred stock could be beneficial for the investor if the common stock price increases.
• The 7.5% cumulative dividend provides a steady return for the investor.

Negatives

• The Series C Preferred Stock is non-voting, limiting the investor's influence on company decisions.
• The conversion of preferred stock to common stock is subject to a beneficial ownership limitation, potentially restricting the investor's stake.
• The company has the right to call the stock after five years, which could limit the investor's long-term gains.

Risks

• The conversion price of the preferred stock is subject to market fluctuations, which could impact the value of the investment.
• The company's ability to pay dividends in cash is not guaranteed, as they have the option to pay in shares of preferred stock.
• The beneficial ownership limitation could restrict the investor's ability to convert all of their preferred stock into common stock.
• The call right held by the company could limit the investor's potential long-term gains.

Future Outlook

The company will use the $6 million capital injection to further its business objectives. The Series C Preferred Stock has a call option after five years, which could impact the long-term capital structure.

Industry Context

This capital raise is a common strategy for biotech companies to fund research and development. The terms of the preferred stock, including the conversion and dividend features, are typical for this type of financing.

Comparison to Industry Standards

• The 7.5% cumulative dividend is within the typical range for preferred stock in the biotech sector, although some companies may offer higher or lower rates depending on their risk profile and financial needs.
• The conversion feature with a floor price is a common mechanism to protect investors from significant downside risk while allowing them to participate in potential upside.
• The beneficial ownership limitation is a standard clause to prevent a single investor from gaining too much control, which is common in venture capital and private equity deals.
• The call option after five years is a standard feature that allows the company to manage its capital structure and potentially reduce its cost of capital in the future. Similar terms can be seen in companies such as XOMA Corporation and Agenus Inc.

Management Changes

Corporate Governance

Related Party Transactions

• The investor is an existing investor and lender to the company and is associated with Dr. Manmohan Patel, an existing investor and beneficial owner of more than 5% of the common stock.

Stakeholder Impact

• Shareholders: The issuance of preferred stock may dilute existing shareholders' ownership, but the capital raise could benefit the company's long-term prospects.
• Investors: The investor receives preferred stock with a fixed dividend and potential for conversion to common stock, subject to certain limitations.
• Employees: The capital raise could provide financial stability and support for the company's operations and growth.
• Creditors: The capital raise could improve the company's financial position and ability to meet its obligations.

Next Steps

• The company will receive $4 million on or before August 30, 2024, and $2 million on or before September 16, 2024.
• The Series C Preferred Stock will begin accruing dividends no later than September 30, 2024.
• The Series C Preferred Stock will be convertible into common stock six months after issuance.
• The company will monitor the conversion of the preferred stock to ensure compliance with the beneficial ownership limitation.

Key Dates

Keywords

Series C Preferred Stock, Securities Purchase Agreement, Capital Raise, Convertible Stock, Beneficial Ownership Limitation, Dividends, Tevogen Bio, Warrants, Investment